Versant Capital Management
AVBP icon

Versant Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Versant Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.5K Buy
710
+287
+68% +$8.79K ﹤0.01% 1924
2026
Q2 		$14.7K Hold
423
– – ﹤0.01% 2083
2026
Q1 		$9.8K Buy
423
+10
+2% +$226 ﹤0.01% 2151
2025
Q4 		$8.31K Buy
413
+223
+117% +$4.64K ﹤0.01% 2073
2025
Q3 		$3.51K Sell
190
-186
-49% -$3.65K ﹤0.01% 2316
2025
Q2 		$8.19K Buy
+376
New +$7.81K ﹤0.01% 1976

Other funds holding AVBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Versant Capital Management's AVBP Position: Q3 2026 in Review

Versant Capital Management increased its ArriVent BioPharma (AVBP) stake by 68% in Q3 2026, buying an estimated $8.79K and bringing the position to 710 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1924.

Versant Capital Management first reported a position in AVBP in Q2 2025 and has held it in 6 quarters since. 67 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Versant Capital Management held 710 shares of ArriVent BioPharma worth $21.5K as of Q3 2026.
  • Versant Capital Management bought 287 ArriVent BioPharma shares in Q3 2026, an estimated $8.79K.
  • ArriVent BioPharma made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1924 holding.
  • Versant Capital Management first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 6 quarters since.
  • 67 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.